Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Andrea Corona Altimmunes GLP-1 drug shows positive results for alcohol use disorder On Tuesday, Altimmune announced topline data from their Phase 2 RECLAIM trial showing that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced the number of heavy drinking days compared to placebo in patients with moderate to severe alcohol use disorder
We go into what science says about the effectiveness of a B12 shot
This adds another layer of evidence to the 2004 Study by Bock-Marquette et al
These tissues can sometimes be slow to recover, particularly when blood flow is limited
US$ 23.27
US$ 23.08
US$ 23.68
US$ 23.91
US$ 29.95
US$ 23.67
